Deal Tracker · Countries

India pharma deals

19 pharma deals involving India — companies based there or deals covering the market — tracked by EPT: licensing, investment & joint ventures. Most active: Biocon, ADCAN Pharma, Dr. Reddy's Laboratories & Adcock Ingram. Latest: Gilead Sciences → Dr. Reddy's Laboratories (Licensing, 16 Nov 2026).

19
deals tracked
15
announced in 2026
$366m
disclosed value (5 deals)
58%
licensing, the top deal type
  • EPT has tracked 19 India pharma deals (2024–2026), 15 of them announced in 2026.
  • The most common structures are licensing (58%), investment (11%) & joint ventures (11%).
  • Values were disclosed for 5 of 19 deals, totalling $366m; the largest is Natco Pharma → Adcock Ingram ($260m, 8 Jul 2026).
  • The most active companies: Biocon (4), ADCAN Pharma (2) & Dr. Reddy's Laboratories (2).

Most active companies

Biocon (4) · ADCAN Pharma (2) · Dr. Reddy's Laboratories (2)

Countries involved

Saudi Arabia (5) · UAE (4) · Malaysia (2) · Brazil (1) · Chile (1) · China (1)

Largest disclosed deals

Questions

How many India pharma deals has EPT tracked?
19 as of 16 Nov 2026, covering 2024–2026; 15 were announced in 2026. The most recent is Gilead Sciences → Dr. Reddy's Laboratories (Licensing, 16 Nov 2026).
What types of India pharma deals are most common?
Licensing: 11 (58%); Equity / Investment: 2 (11%); Joint venture: 2 (11%); Distribution: 1 (5%).
Which companies are most active in India pharma deals?
Biocon (4 deals), ADCAN Pharma (2 deals), Dr. Reddy's Laboratories (2 deals).
What is the largest disclosed India pharma deal?
Natco Pharma → Adcock Ingram: $260m (Equity / Investment, 8 Jul 2026); Orchid Pharma → Laboratorio Libra: $80m (Licensing, 24 Oct 2026); Sandoz → Strides Pharma: $12m (M&A / Acquisition, 17 Mar 2026). Values are as announced by the parties.

Browse deals

By region

GCC (83) · MENA (66) · Africa (17) · Latin America (17) · Southeast Asia (17) · Global (LMICs) (14) · CIS & Central Asia (13) · Türkiye (5) · Global ex-US (1)

By country

Saudi Arabia (69) · UAE (61) · China (31) · Egypt (27) · United States (26) · Oman (20) · Switzerland (18) · Jordan (14) · South Korea (14) · Kazakhstan (13) · Algeria (12) · Türkiye (12) · United Kingdom (11) · Brazil (10) · Kuwait (10) · Iraq (8) · Morocco (8) · Bahrain (7) · Malaysia (7) · Spain (7) · Argentina (6) · Germany (6) · Indonesia (6) · Philippines (6) · Qatar (6) · Italy (5) · Mexico (5) · Vietnam (5) · France (4) · Taiwan (4) · Tunisia (4) · Canada (3) · Chile (3) · Denmark (3) · Greece (3) · Japan (3) · Lebanon (3) · Nigeria (3) · Pakistan (3) · South Africa (3) · Sweden (3) · Thailand (3) · Azerbaijan (2) · Colombia (2) · Ireland (2) · Kenya (2) · Libya (2) · Netherlands (2) · Singapore (2) · Uruguay (2) · Uzbekistan (2)

By year

2026 (193) · 2025 (27) · 2024 (6) · 2022 (3) · 2021 (2)

By therapeutic area

Multi-therapy (64) · Oncology (30) · Metabolic / Diabetes (27) · Cardiovascular (17) · Vaccines (15) · Immunology / Inflammation (13) · Rare / Orphan (9) · Infectious Disease (8) · CNS / Neurology (6) · Ophthalmology (6) · Consumer health (5) · Women's Health (4) · Respiratory (2)